



Press release  
April 4, 2006

# Affibody signs distribution agreement with Abcam

**STOCKHOLM, Sweden, April 4, 2006 - Affibody AB today announced an agreement in which Abcam will market Affibody® Research Reagents in its online catalog.**

Affibody, a Swedish molecular imaging, targeted therapy and biotechnology company, today announced an agreement in which Abcam, a leading antibody supply company, will promote and distribute products from Affibody's portfolio of research reagents worldwide.

"We are delighted with this distribution agreement. Affibody's exciting new class of affinity ligands complement our range of top quality antibodies and further improves our ability to meet the high demand for research reagents worldwide," said Simon Renshaw, New Product Manager at Abcam.

Carl-Johan Dalsgaard, CEO of Affibody, added: "Abcam has an excellent reputation and market penetration and we appreciate that they operate as our distributor as it widens the important global sales channel for Affibody."

For further information, please contact:

Karin Nord,  
Director of Biotechnology, Affibody  
+46 8 59 88 38 53  
karin.nord@affibody.com

Simon Renshaw  
New Product Manager, Abcam  
+44 1223 696033  
simon.renshaw@abcam.com

## **About Affibody**

*Affibody's vision is to be a leading player in the emerging field of molecular imaging and targeted therapeutics, and a preferred partner and provider of high quality biotechnology products. Affibody uses innovative protein-engineering technologies for the development of affinity ligands. A key component of Affibody's technology is the Affibody® molecules, small robust proteins which can be designed to bind to any target protein. The physical characteristics of Affibody® molecules including small size, specific target recognition, ease of production and high stability in a wide range of conditions, give them valuable advantages over other affinity*



*ligand technologies. Affibody has also developed a proprietary Albumin-Binding technology, which allows for prolonging the half-life of biologicals as well as evading immune response.*

*Based on its proprietary technology platform, Affibody has developed a unique oncology pipeline, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The Company also commercializes Affibody® molecules for various biotechnology applications, such as large scale affinity purification, apheresis, sample preparation, protein detection and in vitro diagnostics.*

*Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute in Stockholm. Among the owners of Affibody AB are the investment companies HealthCap, Schroder Ventures Life Sciences and Investor Growth Capital. Affibody is based in Stockholm, Sweden and has 50 employees. Further information is found on: [www.affibody.com](http://www.affibody.com).*

### **About Abcam**

*Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcam was admitted to the AIM market of the London Stock Exchange in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, [www.abcam.com](http://www.abcam.com). The antibodies are sold almost entirely under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of almost 19,000 products, most of which are antibodies, from over 170 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 90 staff.*

*The Company was founded by Dr Jonathan Milner (CEO), Dr David Cleavelly (Chairman) and Professor Tony Kouzarides (non-executive director) in February 1998. Abcam was established with funding provided by friends and family of the founders and business angels. Since establishment, the Company has grown significantly, driven by the increased availability and use of the internet and the expansion of the Company's product base, which in part is due to the rapid growth in the number of protein targets derived from the human genome project. In 2004, Abcam was ranked by Deloitte as the 11th fastest growing technology company in Europe. In April 2005 it was awarded the Queen's Award for Enterprise. The Company reported its first profit in the financial year ended 30 June 2003. In April 2005 the Company moved its headquarters to larger premises in Cambridge, UK and its US subsidiary to larger premises in Cambridge, Massachusetts.*